Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD (original) (raw)
Visual and Anatomical Outcomes of Intravitreal Aflibercept in Eyes with Persistent Subfoveal Fluid Despite Previous Treatments with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration
Umberto De Vico
Retina, 2013
View PDFchevron_right
Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration
Angeliki Androu
International ophthalmology, 2018
View PDFchevron_right
Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab
Stéphane Dumas
Journal of Ophthalmology, 2017
View PDFchevron_right
Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration
Cihan Buyukavsar
Turkish journal of ophthalmology, 2017
View PDFchevron_right
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Laurent Kodjikian
BMC Ophthalmology
View PDFchevron_right
Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
Maria Woodward
Clinical ophthalmology (Auckland, N.Z.), 2016
View PDFchevron_right
Pigment Epithelial Detachment Response to Aflibercept in Neovascular Age-Related Macular Degeneration Refractory to Ranibizumab
Doris Decugis
Retina, 2016
View PDFchevron_right
Super-dose Anti-VEGF (SAVE) Trial: 2.0 mg Intravitreal Ranibizumab for Recalcitrant Neovascular Macular Degeneration–Primary End Point
James Major
Ophthalmology, 2013
View PDFchevron_right
Visual and Anatomical Outcomes of Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration
Francesco Parisi, Magda Gharbiya, Umberto De Vico
BioMed Research International, 2014
View PDFchevron_right
Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography
Natasa Mihailovic
Graefe's Archive for Clinical and Experimental Ophthalmology, 2020
View PDFchevron_right
Short-Term Outcomes of Aflibercept for Neovascular Age-Related Macular Degeneration in Eyes Previously Treated With Other Vascular Endothelial Growth Factor Inhibitors
Timothy Olsen
American Journal of Ophthalmology, 2013
View PDFchevron_right
Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration
Khurram Chaudhary
The British journal of ophthalmology, 2014
View PDFchevron_right
Real Life Data of Treat and Extend Intravitreal Ranibizumab and Aflibercept Therapy in Wet Age-related Macular Degeneration Patients: 3-Year Results
Özgül Uğurtay
Korean Journal of Ophthalmology, 2021
View PDFchevron_right
Outcome of Intravitreal Aflibercept for Refractory Pigment Epithelial Detachment with or Without Subretinal Fluid and Secondary to Age-Related Macular Degeneration
yonguk kim
Retina (Philadelphia, Pa.), 2017
View PDFchevron_right
Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration
Christian Simader
Expert Opinion on Pharmacotherapy, 2012
View PDFchevron_right
AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: The ARI2 Study
Jose Sahel
Retina (Philadelphia, Pa.), 2017
View PDFchevron_right
Aflibercept Therapy for Exudative Age-related Macular Degeneration Resistant to Bevacizumab and Ranibizumab
James Folk, Stephen Russell
American Journal of Ophthalmology, 2013
View PDFchevron_right
Long term results of patients with neovascular age-related macular degeneration switched from other anti-VEGF agents to intravitreal Aflibercept
Hema Ramkumar
International journal of retina and vitreous, 2022
View PDFchevron_right
Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
cynthia santiago
BMC ophthalmology, 2018
View PDFchevron_right
Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning
Yasuo Kurimoto
Clinical ophthalmology (Auckland, N.Z.), 2017
View PDFchevron_right
Response to bevacizumab after treatment with aflibercept in eyes with neovascular AMD
sara kazerounian
European Journal of Ophthalmology, 2016
View PDFchevron_right
How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview
Theodoros Giannopoulos
Advances in Therapy, 2019
View PDFchevron_right
The results of switching between 2 anti-VEGF drugs, bevacizumab and ranibizumab, in the treatment of neovascular age-related macular degeneration
Burak Erden
European Journal of Ophthalmology, 2013
View PDFchevron_right
The Impact of Aflibercept on Diabetic Macular Edema Patients Refractory to Ranibizumab in a Tertiary Care Eye Specialist Hospital, Saudi Arabia
Hassan Al-Dhibi
Pharmacology, Toxicology and Biomedical Reports, 2021
View PDFchevron_right
Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy
Akio Oishi
Scientific Reports, 2019
View PDFchevron_right
Response to Aflibercept After Frequent Re-treatment With Bevacizumab or Ranibizumab in Eyes With Neovascular AMD
Dimple Modi
Ophthalmic Surgery, Lasers and Imaging Retina, 2014
View PDFchevron_right
Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)
Charles Wykoff
British Journal of Ophthalmology, 2014
View PDFchevron_right
Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
Mauricio Maia, Alessandro Castellarin
The British journal of ophthalmology, 2014
View PDFchevron_right
Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
Bhaskar Gupta
International journal of ophthalmology, 2017
View PDFchevron_right
Two Year Study of Aflibercept and Ranibizumab Intravitreal Therapy in Patients with Wet AMD
Anna Heinke
Medicina
View PDFchevron_right
Efficacy of aflibercept for the treatment of chronic non-ischemic CRVO-associated macular edema after treatment with other anti- VEGF agents
Herbert Publications
View PDFchevron_right
Diabetic macular edema treated with intravitreal aflibercept injection after treatment with other anti-VEGF agents (SWAP-TWO study): 6-month interim analysis
amy babiuch
International Journal of Retina and Vitreous, 2019
View PDFchevron_right
Corrigendum to "Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab
Stéphane Dumas
Journal of ophthalmology, 2018
View PDFchevron_right
Anti-VEGF Agents for the Treatment of Pigment Epithelial Detachments Associated with Neovascular Age-related Macular Degeneration: An Evidence-based Approach
Georgios D Panos
Medical hypothesis, discovery and innovation in ophthalmology, 2015
View PDFchevron_right
Efficacy of intravitreal injection of aflibercept in neovascular age-related macular degeneration with or without choroidal vascular hyperpermeability
Masayuki Hata
Investigative ophthalmology & visual science, 2014
View PDFchevron_right